---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Anti-IgE monoclonal antibodies"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Anti-IgE monoclonal antibodies. Topics: Omalizumab as add-on treatment after high-dose antihistamines: 2026 international guideline; FDA-approved indication and dosage in chronic spontaneous urticaria: omalizumab; Anaphylaxis warning: omalizumab; Adverse reactions in pooled CSU trials, Day 1 to Week 12: omalizumab; 12 further topics. 16 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/anti-ige-monoclonal-antibodies"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Anti-IgE monoclonal antibodies

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Anti-IgE Monoclonal Antibodies

<a id="topic-2.2.2.1.2-1"></a>

### Omalizumab as add-on treatment after high-dose antihistamines: 2026 international guideline

> “We recommend adding on omalizumab”
> “for the treatment of patients with CU unresponsive to high doses of 2nd generation H1‐antihistamines.”
> “The recommended initial dose in CSU is 300 mg every 4 weeks as add on to antihistamine treatment. Dosing is independent of total serum IgE and bodyweight”
> “Studies support the use of omalizumab treatment at doses up to 600 mg and intervals of 2 weeks, in patients with insufficient response to standard dosed omalizumab”
> “Patients need to be informed that omalizumab updosing is off‐label.”
> “Drug survival studies, or time to discontinuation, for omalizumab show that the main reason for discontinuation is due to well‐controlled disease and far less due to ineffectiveness or adverse effects”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.2-2"></a>

### FDA-approved indication and dosage in chronic spontaneous urticaria: omalizumab

> “XOLAIR is indicated for the treatment of adults and adolescents 12 years of age and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment.”
> “XOLAIR is not indicated for treatment of other forms of urticaria.”
> “The recommended dosage for chronic spontaneous urticaria (CSU) is XOLAIR 150 mg or 300 mg by subcutaneous injection every 4 weeks.”
> “Dosing of XOLAIR in CSU patients is not dependent on serum IgE (free or total) level or body weight.”
> “The appropriate duration of therapy for CSU has not been evaluated. Periodically reassess the need for continued therapy.”

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

<a id="topic-2.2.2.1.2-3"></a>

### Anaphylaxis warning: omalizumab

> “Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment.”
> “In postmarketing spontaneous reports, the frequency of anaphylaxis attributed to XOLAIR use was estimated to be at least 0.2% of patients based on an estimated exposure of about 57,300 patients from June 2003 through December 2006.”
> “Approximately 60% to 70% of anaphylaxis cases have been reported to occur within the first three doses of XOLAIR, with additional cases occurring sporadically beyond the third dose.”

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

<a id="topic-2.2.2.1.2-4"></a>

### Adverse reactions in pooled CSU trials, Day 1 to Week 12: omalizumab

| Adverse reaction | Omalizumab 150 mg (n=175) | Omalizumab 300 mg (n=412) | Placebo (n=242) |
| --- | --- | --- | --- |
| Nausea | “2 (1.1%)” | “11 (2.7%)” | “6 (2.5%)” |
| Nasopharyngitis | “16 (9.1%)” | “27 (6.6%)” | “17 (7.0%)” |
| Sinusitis | “2 (1.1%)” | “20 (4.9%)” | “5 (2.1%)” |
| Upper respiratory tract infection | “2 (1.1%)” | “14 (3.4%)” | “5 (2.1%)” |
| Arthralgia | “5 (2.9%)” | “12 (2.9%)” | “1 (0.4%)” |
| Headache | “21 (12.0%)” | “25 (6.1%)” | “7 (2.9%)” |
| Cough | “2 (1.1%)” | “9 (2.2%)” | “3 (1.2%)” |

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

> “Adverse reactions are pooled from CSU Trial 2 and the first 12 weeks of CSU Trials 1 and 3.”
> “Injection site reactions of any severity occurred during the studies in more XOLAIR-treated patients [11 patients (2.7%) at 300 mg, 1 patient (0.6%) at 150 mg] compared with 2 placebo-treated patients (0.8%).”

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

<a id="topic-2.2.2.1.2-5"></a>

### Week 12 itch severity, hive count, and UAS7=0 in CSU Trial 1: omalizumab label

| Week 12 outcome | Omalizumab 75 mg | Omalizumab 150 mg | Omalizumab 300 mg | Placebo |
| --- | --- | --- | --- | --- |
| N | “77” | “80” | “81” | “80” |
| Weekly itch severity score, mean change (SD) | “−6.46 (6.14)” | “−6.66 (6.28)” | “−9.40 (5.73)” | “−3.63 (5.22)” |
| Weekly itch severity score, difference in LS means vs placebo | “−2.96” | “−2.95” | “−5.80” | Not applicable |
| Weekly hive count score, mean change (SD) | “−7.36 (7.52)” | “−7.78 (7.08)” | “−11.35 (7.25)” | “−4.37 (6.60)” |

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

> “All patients were required to have a UAS7 of ≥16, and a weekly itch severity score of ≥8 for the 7 days prior to randomization, despite having used an H1 antihistamine for at least 2 weeks.”
> “In CSU Trial 1, a larger proportion of patients treated with XOLAIR 300 mg (36%) reported no itch and no hives (UAS7=0) at Week 12 compared to patients treated with XOLAIR 150 mg (15%), XOLAIR 75 mg (12%), and placebo group (9%). Similar results were observed in CSU Trial 2.”
> “The 75-mg dose did not demonstrate consistent evidence of efficacy and is not approved for use.”

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

<a id="topic-2.2.2.1.2-6"></a>

### ASTERIA I: well-controlled UAS7 ⩽6 and complete response UAS7=0 with omalizumab 300 mg

> “ASTERIA I was a 40-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous omalizumab as add-on therapy for 24 weeks in patients with chronic idiopathic urticaria/spontaneous urticaria (CIU/CSU) who remained symptomatic despite H1 antihistamine treatment at licensed doses.”
> “The omalizumab 300-mg group met all nine secondary end points, including a significant decrease in the duration of time to reach minimally important difference response (⩾5-point decrease) in weekly ISS ( P <0.0001) and higher percentages of patients with well-controlled symptoms (urticaria activity score over 7 days (UAS7) ⩽6: 51.9% vs. 11.3% P <0.0001) and complete response (UAS7=0: 35.8% vs. 8.8% P <0.0001) versus placebo.”

Source: [Saini et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4269803/)

<a id="topic-2.2.2.1.2-7"></a>

### Week 12 itch severity by omalizumab dose: phase 3 randomized trial

> “In this phase 3, multicenter, randomized, double-blind study, we evaluated the efficacy and safety of omalizumab in patients with moderate-to-severe chronic idiopathic urticaria who remained symptomatic despite”
> “We randomly assigned 323 patients to receive three subcutaneous injections, spaced 4 weeks apart, of omalizumab at doses of 75 mg, 150 mg, or 300 mg or placebo, followed by a 16-week observation period.”
> “At week 12, the mean (±SD) change from baseline in the weekly itch-severity score was -5.1±5.6 in the placebo group, -5.9±6.5 in the 75-mg group (P=0.46), -8.1±6.4 in the 150-mg group (P=0.001), and -9.8±6.0 in the 300-mg group (P<0.001).”
> “The frequency of serious adverse events was low, although the rate was higher in the 300-mg group (6%) than in the placebo group (3%) or in either the 75-mg or 150-mg group (1% for each).”

Source: [Maurer et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23432142/)

<a id="topic-2.2.2.1.2-8"></a>

### Week 12 results with omalizumab 300 mg after antihistamines up to 4 times the approved dose plus H2-antihistamines or leukotriene receptor antagonists

> “We sought to evaluate the safety and efficacy of 24 weeks of treatment with omalizumab in patients with persistent CIU/CSU despite treatment with H1-antihistamines at up to 4 times the approved dose plus H2-antihistamines, leukotriene receptor antagonists, or both.”
> “In this phase III study patients were randomized to receive 6 subcutaneous injections at 4-week intervals of either 300 mg of omalizumab or placebo, followed by a 16-week observation period.”
> “At week 12, the mean change from baseline in weekly itch severity score was −8.6 (95% CI, −9.3 to −7.8) in the omalizumab group compared with −4.0 (95% CI, −5.3 to −2.7) in the placebo group (P < .001).”
> “This study shows that approximately half of the patients who received add-on omalizumab achieved UAS7s of 6 or less, and one third were completely itch and hive free (UAS7 = 0).”

Source: [Kaplan et al. (2013)](https://doi.org/10.1016/j.jaci.2013.05.013)

| Week 12 outcome | Omalizumab 300 mg (n = 252) | Placebo (n = 83) |
| --- | --- | --- |
| Change from baseline in UAS7, mean (95% CI) | “−19.0 (−20.6 to −17.4)” | “−8.5 (−11.1 to −5.9)” |
| UAS7 ≤6, no. (%) | “132 (52.4)” | “10 (12.0)” |
| UAS7 = 0, no. (%) | “85 (33.7)” | “4 (4.8)” |

Source: [Kaplan et al. (2013)](https://doi.org/10.1016/j.jaci.2013.05.013)

<a id="topic-2.2.2.1.2-9"></a>

### Pooled randomized trial effects of omalizumab 150 mg and 300 mg: systematic review

> “This systematic review evaluates the efficacy and safety of omalizumab for chronic spontaneous urticaria (CSU).”
> “Ten RCTs including 1620 subjects aged 12 to 75 years old treated with omalizumab for 16 to 40 weeks were evaluated.”
> “Omalizumab 300 mg results in clinically meaningful improvements (moderate certainty) of the UAS7 (MD -11.05; 95%CI -12.87 to -9.24), the ISS7 (MD -4.45; 95%CI -5.39 to -3.51), and QoL (high certainty) (DLQI; MD -4.03; 95% CI -5.56 to -2.5)”
> “Omalizumab 150 mg does not result in clinically meaningful improvement (high certainty) of the urticaria activity score (UAS)7 (mean difference (MD) -5; 95%CI -7.75 to -2.25)”

Source: [Agache et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32767573/)

<a id="topic-2.2.2.1.2-10"></a>

### Real-world effectiveness and adverse events: meta-analysis of 67 observational studies

> “Included studies were observational in design and included at least 1 outcome in common with other studies and at a concurrent time point of exposure to omalizumab. A total of 67 articles (35.2% of those screened) were included in the analysis.”
> “Random-effects meta-analyses were performed.”
> “Omalizumab therapy was associated with an improvement in UAS7 scores (−25.6 points, 95% CI, −28.2 to −23.0; P < .001; 15 studies, 294 patients), an improvement in UAS scores (−4.7 points, 95% CI, −5.0 to −4.4, P < .001; 10 studies, 1158 patients), an average complete response rate of 72.2% (95% CI, 66.1%-78.3%; P < .001; 45 studies, 1158 patients) with an additional average partial response rate of 17.8% (95% CI, 11.7%-23.9%; P < .001; 37 studies, 908 patients), and an average adverse event rate of 4.0% (95% CI, 1.0%-7.0%; P < .001; any level of severity, 47 studies, 1314 patients).”

Source: [Tharp et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6439579/)

<a id="topic-2.2.2.1.2-11"></a>

### Drug survival and reasons for discontinuation: meta-analysis of 8 observational studies

> “Observational clinical studies that reported on time to discontinuation or drug survival outcomes for omalizumab in patients with CU were included.”
> “Eight studies comprising 4516 patients with CU (3167 female individuals [70.1%]; 3276 with chronic spontaneous urticaria [CSU]) were included. The median drug survival for omalizumab was 3.1 years (95% CI, 2.8-3.4).”
> “Long-term drug survival appeared higher in chronic inducible urticaria (with or without concomitant CSU) than in CSU alone (7-year survival, 43%-49% vs 30%). Early discontinuation was primarily due to well-controlled disease. Discontinuation due to adverse events was uncommon.”
> “Autoimmune comorbidity was associated with a higher risk of discontinuation due to lack of efficacy (HR, 2.03; 95% CI, 1.20-3.41)”
> “The results of this systematic review and meta-analysis suggest that omalizumab demonstrates long-term drug survival in CU, with discontinuation more often due to disease control than adverse events.”

Source: [Altayf et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42714921/)

<a id="topic-2.2.2.1.2-12"></a>

### Omalizumab in a network meta-analysis of systemic treatments for the Joint Task Force guideline update

> “We systematically synthesized the comparative benefits and harms of systemic treatments for chronic urticaria.”
> “As part of updating the AAAAI/ACAAI JTFPP chronic urticaria guidelines”
> “Random effects Bayesian network meta-analyses addressed urticaria activity (comprising itch and wheal scores), angioedema activity, health-related quality of life, and adverse events.”
> “We included 93 studies (n = 11,398; mostly adult and adolescent participants across 83 randomized trials and 10 nonrandomized studies) that evaluated 42 interventions. With high certainty, standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib are among the most effective for improving multiple patient-important outcomes.”
> “Standard-dose omalizumab (MD −8.37 [95% CrI −10.28 to −6.46]; high certainty), and remibrutinib (MD −7.65 [95% CrI −11.75 to −3.54]; high certainty) are among the most effective, while low-dose omalizumab (MD −5.25 [95% CrI −7.83 to −2.68]; high certainty) is among the intermediate effective.”
> “Standard-dose omalizumab (MD 8.75% more [95% CrI 1.93% to 15.56% more]; high certainty) and remibrutinib (MD 15.00% more [95% CrI 3.16% to 26.84% more]; high certainty) are among the most effective.”
> “Nonrandomized data (n = 149) suggest that 69% (95% CI 59% to 78%) of patients with disease refractory to standard-dose omalizumab may experience response (ie, UAS7 ≤ 6 or Urticaria Control Test [UCT] ≥ 12) with higher doses or more frequent administration.”
> “High-certainty evidence demonstrates that omalizumab (OR 0.92 [95% CrI 0.58 to 1.45]; RD 0.2% less [95% CrI 1% less to 1% more]) is not different from placebo”

Source: [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004)

<a id="topic-2.2.2.1.2-13"></a>

### Omalizumab 300 mg compared with dupilumab and remibrutinib: network meta-analysis of 15 studies

> “This study aims to compare the relative efficacy of omalizumab, dupilumab, and remibrutinib in CSU.”
> “Frequentist random-effects network meta-analysis were conducted in R.”
> “Fifteen studies (4,913 patients) were included. Omalizumab 300 mg demonstrated the greatest efficacy in UAS7, ISS7, symptom remission, and disease control at both timepoints.”
> “Lower omalizumab doses lacked durability at 24 weeks.”

Source: [Xiong et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41186128/)

<a id="topic-2.2.2.1.2-14"></a>

### Ligelizumab not superior to omalizumab: PEARL-1 and PEARL-2 phase 3 trials

> “PEARL-1 and PEARL-2 were identically designed randomised, double-blind, active-controlled and placebo-controlled parallel-group studies.”
> “Between Oct 17, 2018, and Oct 26, 2021, 2057 adult patients were randomly allocated across both studies (72 mg ligelizumab n=614; 120 mg ligelizumab n=616; 300 mg omalizumab n=618, and placebo n=209).”
> “Both doses of ligelizumab were superior to placebo (p<0·0001), but not to omalizumab, in both studies.”
> “In the phase 3 PEARL studies, ligelizumab demonstrated superior efficacy versus placebo but not versus omalizumab.”

Source: [Maurer et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38008109/)

<a id="topic-2.2.2.1.2-15"></a>

### Omalizumab biosimilar omalizumab-igec: FDA-approved indication in chronic spontaneous urticaria

> “OMLYCLO® (omalizumab-igec) injection, for subcutaneous use Initial U.S. Approval: 2025 OMLYCLO® (omalizumab-igec) is biosimilar”
> “to XOLAIR® (omalizumab)”
> “Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment (1.4)”
> “Chronic Spontaneous Urticaria: OMLYCLO 150 or 300 mg SC every 4 weeks. Dosing in CSU is not dependent on serum IgE level or body weight. (2.5)”

Source: [Omlyclo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761399s004lbl.pdf)

<a id="topic-2.2.2.1.2-16"></a>

### Biosimilar CT-P39 compared with reference omalizumab: randomized active-controlled phase 3 equivalence trial

> “This double‐blind, randomized, active‐controlled Phase 3 study ( NCT04426890 ) included two 12‐week treatment periods (TPs).”
> “In TP1, 619 patients were randomized (CT‐P39 300 mg, n = 204; ref‐OMA 300 mg, n = 205; CT‐P39 150 mg, n = 107; ref‐OMA 150 mg, n = 103). Equivalence was demonstrated between CT‐P39 300 mg and ref‐OMA 300 mg for mean change from baseline in ISS7 at week 12”
> “Secondary efficacy, quality of life, pharmacokinetic, safety, and immunogenicity outcomes were comparable between groups at a given dose level, with no evident impact of switching.”

Source: [Saini et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368742/)

Additional sources: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
